Company Encyclopedia
View More
name
JAFRON
300529.SZ
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps.
890.25 B
300529.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking32/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.34%B
    • Profit Margin23.64%A
    • Gross Margin80.45%A
  • Growth ScoreD
    • Revenue YoY-22.58%E
    • Net Profit YoY-40.11%D
    • Total Assets YoY-1.02%D
    • Net Assets YoY4.11%C
  • Cash ScoreD
    • Cash Flow Margin422.93%C
    • OCF YoY-22.58%E
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreB
    • Gearing Ratio38.07%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JAFRON released its performance for the first three quarters, with a net profit attributable to the parent company of 453 million yuan, a decrease of 42.75%

    According to the Zhitong Finance APP, JAFRON released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.556 billion yuan, a year-on-year decrease of 29.13%. The net profit attributable to shareholders of the listed company was 453 million yuan, a year-on-year decrease of 42.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 438 million yuan, a year-on-year decrease of 41.87%. The basic earnings per share were 0.59 yuan

    Zhitong·
    SZ
    300529
    -0.15%
    Zhitong·
    SZ
    300529
    -0.15%

    EU Grants Quality Management Certificate to Jafron Biomedical's Blood Purification Tubing Sets

    Jafron Biomedical obtained a quality management system certificate from the European Union for its extracorporeal tubing sets for blood purification, according to a Thursday filing with the Shenzhen bourse. The device uses non-phthalate plasticizers, which are safer compared with phthalate plasticizers, the filing said.

    Trading View·
    SZ
    300529
    -0.15%
    Trading View·
    SZ
    300529
    -0.15%

    JAFRON: The extracorporeal circulation blood pathway of the blood purification device has obtained EU MDR certification

    According to the Zhitong Finance APP, JAFRON announced that the company recently received a notification from the EU announcement agency, stating that the company's blood purification device's extracorporeal circulation blood path has obtained the EU MDR certification issued in accordance with the EU Medical Devices Regulation (EU) 2017/745 (referred to as "MDR"), allowing it to be sold in EU countries and other countries that recognize EU CE certification

    Zhitong·
    SZ
    300529
    -0.15%
    Zhitong·
    SZ
    300529
    -0.15%

    Jafron Biomedical's Single-Use Waste Liquid Bag Gets Registration Certificate

    Jafron Biomedical's single-use waste liquid bag obtained a Class II medical device registration certificate from China's Guangdong Provincial Medical Products Administration, according to a Shenzhen bourse filing on Wednesday. The device is used for collecting dialysis waste liquid during hemodialysis or hemofiltration treatments. The certificate is valid until May 26, 2030, the Chinese blood purification company said. The company's shares rose 1% in recent trade.

    Trading View·
    SZ
    300529
    -0.15%
    Trading View·
    SZ
    300529
    -0.15%

    JAFRON released its first-quarter performance, with a net profit attributable to the parent company of 189 million yuan, a year-on-year decrease of 33.71%

    According to the Zhitong Finance APP, JAFRON released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 548 million yuan, a year-on-year decrease of 26.40%. The net profit attributable to shareholders of the listed company was 189 million yuan, a year-on-year decrease of 33.71%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 184 million yuan, a year-on-year decrease of 32.15%

    Zhitong·
    SZ
    300529
    -0.15%
    Zhitong·
    SZ
    300529
    -0.15%
    © 2025 Longbridge｜Disclaimer